Skip to main content

Passage BIO, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

PASG$3.43-13.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.

​​​​​​​​​​​
ExhibitNumberDescriptionFormFile No.ExhibitFilingDateFiled/FurnishedHerewith
​​​​​​​​​​​
​​​​​​​​​​​
10.1˄†​Amendment to the Exclusive License Agreement (GM1), dated May 7,2025, by and between the Registrant and Gemma Biotherapeutics, Inc.​​​​​​​X
​​​​​​​​​​​
10.2˄​Amendment to the Exclusive License Agreement (Krabbe), dated May 7, 2025, by and between the Registrant and Gemma Biotherapeutics, Inc.​​​​​​​X
​​​​​​​​​​​
10.3˄​Amendment to the Exclusive License Agreement (MLD), dated May 7, 2025, by and between the Registrant and Gemma Biotherapeutics, Inc.​​​​​​​X
​​​​​​​​​​​
31.1​Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.​​​​​​​X
​​​​​​​​​​​
31.2​Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.​​​​​​​X
​​​​​​​​​​​
32.1*​Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.​​​​​​​​X
​​​​​​​​​​​
32.2*​Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.​​​​​​​X
​​​​​​​​​​​
101.INS​Inline XBRL Instance Document​​​​​​​X
​​​​​​​​​​​
101.SCH​Inline XBRL Taxonomy Extension Schema Document​​​​​​​X
​​​​​​​​​​​
101.CAL​Inline XBRL Taxonomy ExtensionCalculation Linkbase Document​​​​​​​X
​​​​​​​​​​​
101.DEF​Inline XBRL Taxonomy Extension​​​​​​​X
​​Definition Linkbase Document​​​​​​​​
​​​​​​​​​​​
101.LAB​Inline XBRL Taxonomy Extension LabelLinkbase Document​​​​​​​​X
101.PRE​Inline XBRL Taxonomy ExtensionPresentation Linkbase Document​​​​​​​​X
104​Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)​​​​​​​X

ad

​​​
​​​
˄​Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.
†​Registrant has omitted portions of this exhibit as permitted under Item 601(b)(10) of Regulation S-K.
*​This certification is deemed not filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.